Timmerman JM - Search Results

1

Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.

Young PA, Morrison SL, Timmerman JM. Young PA, et al. Among authors: timmerman jm. Semin Oncol. 2014 Oct;41(5):623-36. doi: 10.1053/j.seminoncol.2014.08.002. Epub 2014 Aug 12. Semin Oncol. 2014. PMID: 25440607 Free PMC article. Review.

2

Vaccine therapies for non-Hodgkin's lymphoma.

Timmerman JM. Timmerman JM. Curr Treat Options Oncol. 2002 Aug;3(4):307-15. doi: 10.1007/s11864-002-0030-3. Curr Treat Options Oncol. 2002. PMID: 12074767 Review.

3

Immunotherapy for lymphomas.

Timmerman JM. Timmerman JM. Int J Hematol. 2003 Jun;77(5):444-55. doi: 10.1007/BF02986612. Int J Hematol. 2003. PMID: 12841382 Review.

4

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.

Xuan C, Steward KK, Timmerman JM, Morrison SL. Xuan C, et al. Among authors: timmerman jm. Blood. 2010 Apr 8;115(14):2864-71. doi: 10.1182/blood-2009-10-250555. Epub 2010 Feb 4. Blood. 2010. PMID: 20139095 Free PMC article.

5

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. Trinh KR, et al. Among authors: timmerman jm. J Immunother. 2013 Jun;36(5):305-18. doi: 10.1097/CJI.0b013e3182993eb9. J Immunother. 2013. PMID: 23719241 Free PMC article.

6

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.

Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG. Yamada DH, et al. Among authors: timmerman jm. Immunity. 2015 Feb 17;42(2):379-390. doi: 10.1016/j.immuni.2015.01.005. Epub 2015 Feb 10. Immunity. 2015. PMID: 25680277 Free PMC article.

7

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.

Vasuthasawat A, Yoo EM, Trinh KR, Lichtenstein A, Timmerman JM, Morrison SL. Vasuthasawat A, et al. Among authors: timmerman jm. MAbs. 2016 Oct;8(7):1386-1397. doi: 10.1080/19420862.2016.1207030. Epub 2016 Jun 30. MAbs. 2016. PMID: 27362935 Free PMC article.

8

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.

Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM. Young PA, et al. Among authors: timmerman jm. J Interferon Cytokine Res. 2018 Jun;38(6):239-254. doi: 10.1089/jir.2018.0030. J Interferon Cytokine Res. 2018. PMID: 29920129 Free PMC article.

9

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1^-HK2⁺ Multiple Myeloma.

Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR. Xu S, et al. Among authors: timmerman jm. Cancer Res. 2019 May 15;79(10):2748-2760. doi: 10.1158/0008-5472.CAN-18-2799. Epub 2019 Mar 18. Cancer Res. 2019. PMID: 30885978 Free PMC article.

10

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.

Young PA, Gaut D, Kimaiyo DK, Grotts J, Romero T, Chute J, Schiller G, de Vos S, Eradat HA, Timmerman J. Young PA, et al. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):468-479. doi: 10.1016/j.clml.2020.02.009. Epub 2020 Feb 20. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32229199 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters